Evidence-based guidelines on the therapeutic use of repetitive
transcranial magnetic stimulation (rTMS): An update (2014-2018)

J 2020

Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)

LEFAUCHEUR, J.P., A. ALEMAN, C. BAEKEN, D.H. BENNINGER, J. BRUNELIN et. al.

Basic information

Original name

Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)

Authors

Edition

Clinical Neurophysiology, Clare, Elsevier Ireland, 2020, 1388-2457

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30210 Clinical neurology

Country of publisher

Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.708

RIV identification code

RIV/00216224:14740/20:00118597

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1016/j.clinph.2019.11.002

UT WoS

000507859400021

Keywords in English

Cortex; Indication; Neurology; Neuromodulation; Noninvasive brain stimulation; Psychiatry; Treatment

Abstract

V originále

A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150-206]. These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-8 or a Hl-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for: HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia; HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respectively, in Parkinson's disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spasticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression. Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recommendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols, replicated in a sufficient number of independent studies. This does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance. (C) 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V.

Links

NV16-31868A, research and development project

Name: Ovlivnění kognitivních funkcí a konektivity mozku pomocí neinvazivní mozkové stimulace u pacientů s mírnou kognitivní poruchou u Alzheimerovy choroby

Citovat

LEFAUCHEUR, J.P., A. ALEMAN, C. BAEKEN, D.H. BENNINGER, J. BRUNELIN, V. DI LAZZARO, S.R. FILIPOVIC, C. GREFKES, A. HASAN, F.C. HUMMEL, S.K. JAASKELAINEN, B. LANGGUTH, L. LEOCANI, A. LONDERO, R. NARDONE, J.P. NGUYEN, T. NYFFELER, A.J. OLIVEIRA-MAIA, A. OLIVIERO, F. PADBERG, U. PALM, W. PAULUS, E. POULET, A. QUARTARONE, F. RACHID, Irena REKTOROVÁ, S. ROSSI, H. SAHLSTEN, M. SCHECKLMANN, D. SZEKELY and U. ZIEMANN. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clinical Neurophysiology. Clare: Elsevier Ireland, 2020, vol. 131, No 2, p. 474-528. ISSN 1388-2457. Available from: https://dx.doi.org/10.1016/j.clinph.2019.11.002.

@article{1631643,
   author = {Lefaucheur, J.P. and Aleman, A. and Baeken, C. and Benninger, D.H. and Brunelin, J. and Di Lazzaro, V. and Filipovic, S.R. and Grefkes, C. and Hasan, A. and Hummel, F.C. and Jaaskelainen, S.K. and Langguth, B. and Leocani, L. and Londero, A. and Nardone, R. and Nguyen, J.P. and Nyffeler, T. and OliveiraandMaia, A.J. and Oliviero, A. and Padberg, F. and Palm, U. and Paulus, W. and Poulet, E. and Quartarone, A. and Rachid, F. and Rektorová, Irena and Rossi, S. and Sahlsten, H. and Schecklmann, M. and Szekely, D. and Ziemann, U.},
   article_location = {Clare},
   article_number = {2},
   doi = {http://dx.doi.org/10.1016/j.clinph.2019.11.002},
   keywords = {Cortex; Indication; Neurology; Neuromodulation; Noninvasive brain stimulation; Psychiatry; Treatment},
   language = {eng},
   issn = {1388-2457},
   journal = {Clinical Neurophysiology},
   title = {Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)},
   url = {https://www.sciencedirect.com/science/article/pii/S1388245719312799?via%3Dihub},
   volume = {131},
   year = {2020}
}

TY  - JOUR
ID  - 1631643
AU  - Lefaucheur, J.P. - Aleman, A. - Baeken, C. - Benninger, D.H. - Brunelin, J. - Di Lazzaro, V. - Filipovic, S.R. - Grefkes, C. - Hasan, A. - Hummel, F.C. - Jaaskelainen, S.K. - Langguth, B. - Leocani, L. - Londero, A. - Nardone, R. - Nguyen, J.P. - Nyffeler, T. - Oliveira-Maia, A.J. - Oliviero, A. - Padberg, F. - Palm, U. - Paulus, W. - Poulet, E. - Quartarone, A. - Rachid, F. - Rektorová, Irena - Rossi, S. - Sahlsten, H. - Schecklmann, M. - Szekely, D. - Ziemann, U.
PY  - 2020
TI  - Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)
JF  - Clinical Neurophysiology
VL  - 131
IS  - 2
SP  - 474-528
EP  - 474-528
PB  - Elsevier Ireland
SN  - 13882457
KW  - Cortex
KW  - Indication
KW  - Neurology
KW  - Neuromodulation
KW  - Noninvasive brain stimulation
KW  - Psychiatry
KW  - Treatment
UR  - https://www.sciencedirect.com/science/article/pii/S1388245719312799?via%3Dihub
L2  - https://www.sciencedirect.com/science/article/pii/S1388245719312799?via%3Dihub
N2  - A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150-206]. These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-8 or a Hl-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for: HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia; HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respectively, in Parkinson's disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spasticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression. Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recommendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols, replicated in a sufficient number of independent studies. This does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance. (C) 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V.
ER  -

LEFAUCHEUR, J.P., A. ALEMAN, C. BAEKEN, D.H. BENNINGER, J. BRUNELIN, V. DI LAZZARO, S.R. FILIPOVIC, C. GREFKES, A. HASAN, F.C. HUMMEL, S.K. JAASKELAINEN, B. LANGGUTH, L. LEOCANI, A. LONDERO, R. NARDONE, J.P. NGUYEN, T. NYFFELER, A.J. OLIVEIRA-MAIA, A. OLIVIERO, F. PADBERG, U. PALM, W. PAULUS, E. POULET, A. QUARTARONE, F. RACHID, Irena REKTOROVÁ, S. ROSSI, H. SAHLSTEN, M. SCHECKLMANN, D. SZEKELY and U. ZIEMANN. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). \textit{Clinical Neurophysiology}. Clare: Elsevier Ireland, 2020, vol.~131, No~2, p.~474-528. ISSN~1388-2457. Available from: https://dx.doi.org/10.1016/j.clinph.2019.11.002.

Detailed Information on Publication Record